Isabl
YC W20New York City, US · Founded 2020 · 5 employees · 3 known investors
Isabl develops whole genome and transcriptome sequencing technology for cancer diagnosis, delivering comprehensive genomic profiling and treatment options to physicians and research teams. The company provides rapid cancer diagnostic tests in clinically relevant timeframes to improve outcomes for cancer patients globally.
Also known as Isabl Technologies · Isabl Inc.
Founders & leadership· Y Combinator alumni (W20)
Isabl was founded in 2020 by Juan Medina, Andrew Kung, and Elli Papaemmanuil.
Investors · 3
Company profile
researched Aug 2026Isabl Inc. is a cancer genomics company that analyzes the complete tumor genome and transcriptome (whole genome and transcriptome sequencing, or WGTS) rather than relying on targeted gene panels. The company positions this approach as a way to identify cancer-associated mutations in every sample and to broaden biomarker discovery for patients who do not benefit from existing panel-based diagnostic tests.
The company's core product, Isabl GxT, is described as a genomic test providing complete analysis of the entire tumor genome and transcriptome, and Isabl states it has received FDA Breakthrough Device Designation for the technology. Isabl markets its capability as a software-as-a-service offering for WGTS.
Founding story
The company originated as a spin-off from Memorial Sloan Kettering Cancer Center in 2020.
Business model
Isabl offers its whole genome and transcriptome sequencing (WGTS) capability as a software-as-a-service product, with prospective customers invited to schedule meetings to learn more.
Traction
Isabl reports receiving FDA Breakthrough Device Designation for its GxT technology and backing from investors including Two Sigma Ventures, Y Combinator and BoxOne Ventures.
▸Full profile — market position, technology, go-to-market, history
Market position
Isabl differentiates itself from panel-based tumor diagnostic tests by analyzing the full tumor genome and transcriptome, describing GxT as the most comprehensive genomic test in cancer.
Whole genome and transcriptome coverage rather than targeted panels, enabling detection of cancer-associated mutations across every sample and broader biomarker discovery; FDA Breakthrough Device Designation for the GxT test.
Technology
Isabl's GxT technology performs sequencing and analysis across 100% of the tumor genome and transcriptome, in contrast to panel-based tests that examine a limited set of genes. The company describes GxT as its most comprehensive genomic test in cancer and states it holds FDA Breakthrough Device Designation.
Go-to-market
Direct engagement with prospective customers via meeting requests on the company website for its WGTS SaaS offering.
History
Isabl Inc. spun off from Memorial Sloan Kettering Cancer Center in 2020. The company states it has been funded by Two Sigma Ventures, Y Combinator, BoxOne Ventures, and others.
Compiled by commissioned research from 1 cited public sources — announcements, filings, and press listed under research sources below.
Timeline · 2
launches, deals, and filingsIsabl Inc. was established as a spin-off from Memorial Sloan Kettering Cancer Center in 2020.
The company states it is a recipient of the FDA Breakthrough Device Designation for its GxT whole genome and transcriptome cancer test.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
In the news
▸Research sources · 1
primary sources listed
- Isablisabl.io · web
1 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Isabl do?
- Isabl offers whole-genome and whole-transcriptome sequencing analysis of tumors for comprehensive cancer biomarker profiling.
- Who founded Isabl?
- Isabl was founded by Juan Medina, Andrew Kung, Elli Papaemmanuil in 2020.
- Who are Isabl's investors?
- Isabl's investors include Y Combinator, Two Sigma Ventures, Evolution VC Partners.
- Where is Isabl headquartered?
- Isabl is headquartered in New York City, US.